Therapeutic treatment with the antiinflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology
Dive into the research topics of 'Therapeutic treatment with the antiinflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology'. Together they form a unique fingerprint.